Does the media favor HUMA or SLN?

In the previous week, Silence Therapeutics had 12 more articles in the media than Humacyte. MarketBeat recorded 17 mentions for Silence Therapeutics and 5 mentions for Humacyte. Silence Therapeutics' average media sentiment score of 0.84 beat Humacyte's score of 0.55 indicating that Silence Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Humacyte 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Silence Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate HUMA or SVA?

Humacyte currently has a consensus price target of $6.11, indicating a potential upside of 850.97%. Given Humacyte's stronger consensus rating and higher possible upside, equities research analysts plainly believe Humacyte is more favorable than Sinovac Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Humacyte 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75 Sinovac Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings & valuation, HUMA or SVA?

Humacyte has higher earnings, but lower revenue than Sinovac Biotech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Humacyte $2.04M 87.45 -$40.83M -$0.49 N/A Sinovac Biotech $386.01M 1.67 -$59.68M N/A N/A

Does the media favor HUMA or FDMT?

In the previous week, 4D Molecular Therapeutics had 12 more articles in the media than Humacyte. MarketBeat recorded 17 mentions for 4D Molecular Therapeutics and 5 mentions for Humacyte. Humacyte's average media sentiment score of 0.55 beat 4D Molecular Therapeutics' score of 0.53 indicating that Humacyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Humacyte 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 4D Molecular Therapeutics 7 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CBIO or HUMA?

In the previous week, Humacyte had 3 more articles in the media than Crescent Biopharma. MarketBeat recorded 5 mentions for Humacyte and 2 mentions for Crescent Biopharma. Crescent Biopharma's average media sentiment score of 0.67 beat Humacyte's score of 0.55 indicating that Crescent Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crescent Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Humacyte 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, HUMA or MDXG?

MiMedx Group has higher revenue and earnings than Humacyte. Humacyte is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Humacyte $2.04M 87.45 -$40.83M -$0.49 N/A MiMedx Group $418.63M 1.51 $48.58M $0.04 108.25

Is HUMA or MDXG more profitable?

MiMedx Group has a net margin of 1.76% compared to Humacyte's net margin of -4,556.29%. MiMedx Group's return on equity of 12.09% beat Humacyte's return on equity. Company Net Margins Return on Equity Return on Assets Humacyte -4,556.29% -983.32% -88.84% MiMedx Group 1.76% 12.09% 9.22%

Does the media prefer HUMA or MDXG?

In the previous week, Humacyte and Humacyte both had 5 articles in the media. Humacyte's average media sentiment score of 0.55 beat MiMedx Group's score of 0.16 indicating that Humacyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Humacyte 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MiMedx Group 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Humacyte (HUMA) Competitors

$0.64 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Compare

HUMA vs. SLN, SVA, FDMT, CBIO, and MDXG

Should you buy Humacyte stock or one of its competitors? Humacyte's main competitors and comparable companies include Silence Therapeutics (SLN), Sinovac Biotech (SVA), 4D Molecular Therapeutics (FDMT), Crescent Biopharma (CBIO), and MiMedx Group (MDXG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Humacyte compare to Silence Therapeutics?

Humacyte (NASDAQ:HUMA) and Silence Therapeutics (NASDAQ:SLN) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

In the previous week, Silence Therapeutics had 12 more articles in the media than Humacyte. MarketBeat recorded 17 mentions for Silence Therapeutics and 5 mentions for Humacyte. Silence Therapeutics' average media sentiment score of 0.84 beat Humacyte's score of 0.55 indicating that Silence Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Humacyte	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Silence Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Humacyte has higher revenue and earnings than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Humacyte	$2.04M	87.45	-$40.83M	-$0.49	N/A
Silence Therapeutics	$560K	1,426.76	-$88.61M	-$1.28	N/A

44.7% of Humacyte shares are owned by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are owned by institutional investors. 3.1% of Humacyte shares are owned by company insiders. Comparatively, 3.0% of Silence Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Humacyte has a beta of 2.54, indicating that its stock price is 154% more volatile than the broader market. Comparatively, Silence Therapeutics has a beta of 1.39, indicating that its stock price is 39% more volatile than the broader market.

Humacyte currently has a consensus price target of $6.11, indicating a potential upside of 850.97%. Silence Therapeutics has a consensus price target of $53.50, indicating a potential upside of 303.17%. Given Humacyte's higher probable upside, equities analysts plainly believe Humacyte is more favorable than Silence Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Humacyte has a net margin of -4,556.29% compared to Silence Therapeutics' net margin of -8,943.86%. Silence Therapeutics' return on equity of -106.94% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Humacyte	-4,556.29%	-983.32%	-88.84%
Silence Therapeutics	-8,943.86%	-106.94%	-47.99%

Summary

Humacyte beats Silence Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Humacyte compare to Sinovac Biotech?

Humacyte (NASDAQ:HUMA) and Sinovac Biotech (NASDAQ:SVA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, media sentiment, profitability and risk.

Humacyte has higher earnings, but lower revenue than Sinovac Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Humacyte	$2.04M	87.45	-$40.83M	-$0.49	N/A
Sinovac Biotech	$386.01M	1.67	-$59.68M	N/A	N/A

Humacyte has a beta of 2.54, suggesting that its stock price is 154% more volatile than the broader market. Comparatively, Sinovac Biotech has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market.

Humacyte currently has a consensus price target of $6.11, indicating a potential upside of 850.97%. Given Humacyte's stronger consensus rating and higher possible upside, equities research analysts plainly believe Humacyte is more favorable than Sinovac Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Sinovac Biotech has a net margin of 0.00% compared to Humacyte's net margin of -4,556.29%. Sinovac Biotech's return on equity of 0.00% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Humacyte	-4,556.29%	-983.32%	-88.84%
Sinovac Biotech	N/A	N/A	N/A

In the previous week, Humacyte had 5 more articles in the media than Sinovac Biotech. MarketBeat recorded 5 mentions for Humacyte and 0 mentions for Sinovac Biotech. Humacyte's average media sentiment score of 0.55 beat Sinovac Biotech's score of 0.00 indicating that Humacyte is being referred to more favorably in the media.

Company	Overall Sentiment
Humacyte	Positive
Sinovac Biotech	Neutral

44.7% of Humacyte shares are held by institutional investors. 3.1% of Humacyte shares are held by insiders. Comparatively, 12.8% of Sinovac Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Humacyte beats Sinovac Biotech on 9 of the 14 factors compared between the two stocks.

How does Humacyte compare to 4D Molecular Therapeutics?

Humacyte (NASDAQ:HUMA) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.

In the previous week, 4D Molecular Therapeutics had 12 more articles in the media than Humacyte. MarketBeat recorded 17 mentions for 4D Molecular Therapeutics and 5 mentions for Humacyte. Humacyte's average media sentiment score of 0.55 beat 4D Molecular Therapeutics' score of 0.53 indicating that Humacyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Humacyte	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
4D Molecular Therapeutics	7 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

4D Molecular Therapeutics has a net margin of -194.74% compared to Humacyte's net margin of -4,556.29%. 4D Molecular Therapeutics' return on equity of -41.33% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Humacyte	-4,556.29%	-983.32%	-88.84%
4D Molecular Therapeutics	-194.74%	-41.33%	-35.90%

44.7% of Humacyte shares are owned by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. 3.1% of Humacyte shares are owned by company insiders. Comparatively, 7.9% of 4D Molecular Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Humacyte has a beta of 2.54, suggesting that its share price is 154% more volatile than the broader market. Comparatively, 4D Molecular Therapeutics has a beta of 2.73, suggesting that its share price is 173% more volatile than the broader market.

Humacyte presently has a consensus target price of $6.11, suggesting a potential upside of 850.97%. 4D Molecular Therapeutics has a consensus target price of $29.63, suggesting a potential upside of 87.14%. Given Humacyte's higher probable upside, equities analysts plainly believe Humacyte is more favorable than 4D Molecular Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Humacyte has higher earnings, but lower revenue than 4D Molecular Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Humacyte	$2.04M	87.45	-$40.83M	-$0.49	N/A
4D Molecular Therapeutics	$85.21M	10.26	-$140.11M	-$2.63	N/A

Summary

4D Molecular Therapeutics beats Humacyte on 10 of the 16 factors compared between the two stocks.

How does Humacyte compare to Crescent Biopharma?

Crescent Biopharma (NASDAQ:CBIO) and Humacyte (NASDAQ:HUMA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

75.2% of Crescent Biopharma shares are held by institutional investors. Comparatively, 44.7% of Humacyte shares are held by institutional investors. 24.8% of Crescent Biopharma shares are held by company insiders. Comparatively, 3.1% of Humacyte shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Humacyte had 3 more articles in the media than Crescent Biopharma. MarketBeat recorded 5 mentions for Humacyte and 2 mentions for Crescent Biopharma. Crescent Biopharma's average media sentiment score of 0.67 beat Humacyte's score of 0.55 indicating that Crescent Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crescent Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Humacyte	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Crescent Biopharma has a beta of 1.23, meaning that its stock price is 23% more volatile than the broader market. Comparatively, Humacyte has a beta of 2.54, meaning that its stock price is 154% more volatile than the broader market.

Crescent Biopharma has a net margin of 0.00% compared to Humacyte's net margin of -4,556.29%. Crescent Biopharma's return on equity of -101.50% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crescent Biopharma	N/A	-101.50%	-86.86%
Humacyte	-4,556.29%	-983.32%	-88.84%

Humacyte has lower revenue, but higher earnings than Crescent Biopharma. Crescent Biopharma is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crescent Biopharma	$10.84M	58.76	-$153.94M	-$6.72	N/A
Humacyte	$2.04M	87.45	-$40.83M	-$0.49	N/A

Crescent Biopharma presently has a consensus price target of $29.40, indicating a potential upside of 71.43%. Humacyte has a consensus price target of $6.11, indicating a potential upside of 850.97%. Given Humacyte's stronger consensus rating and higher probable upside, analysts clearly believe Humacyte is more favorable than Crescent Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crescent Biopharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Humacyte beats Crescent Biopharma on 9 of the 17 factors compared between the two stocks.

How does Humacyte compare to MiMedx Group?

Humacyte (NASDAQ:HUMA) and MiMedx Group (NASDAQ:MDXG) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations and institutional ownership.

In the previous week, Humacyte and Humacyte both had 5 articles in the media. Humacyte's average media sentiment score of 0.55 beat MiMedx Group's score of 0.16 indicating that Humacyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Humacyte	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MiMedx Group	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Humacyte currently has a consensus price target of $6.11, indicating a potential upside of 850.97%. MiMedx Group has a consensus price target of $8.43, indicating a potential upside of 94.66%. Given Humacyte's stronger consensus rating and higher probable upside, analysts clearly believe Humacyte is more favorable than MiMedx Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

MiMedx Group has a net margin of 1.76% compared to Humacyte's net margin of -4,556.29%. MiMedx Group's return on equity of 12.09% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Humacyte	-4,556.29%	-983.32%	-88.84%
MiMedx Group	1.76%	12.09%	9.22%

Humacyte has a beta of 2.54, meaning that its stock price is 154% more volatile than the broader market. Comparatively, MiMedx Group has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market.

MiMedx Group has higher revenue and earnings than Humacyte. Humacyte is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Humacyte	$2.04M	87.45	-$40.83M	-$0.49	N/A
MiMedx Group	$418.63M	1.51	$48.58M	$0.04	108.25

44.7% of Humacyte shares are owned by institutional investors. Comparatively, 79.2% of MiMedx Group shares are owned by institutional investors. 3.1% of Humacyte shares are owned by company insiders. Comparatively, 2.5% of MiMedx Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

MiMedx Group beats Humacyte on 8 of the 15 factors compared between the two stocks.

Get Humacyte News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HUMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HUMA vs. The Competition

Export

Metric	Humacyte	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$178.40M	$4.01B	$7.33B	$12.82B
Dividend Yield	N/A	3.64%	2.54%	10.78%
P/E Ratio	-1.31	11.68	272.90	24.25
Price / Sales	87.45	1,352.95	624.39	94.51
Price / Cash	N/A	44.94	29.03	36.90
Price / Book	32.11	17.38	11.25	6.42
Net Income	-$40.83M	-$22.72M	$3.47B	$348.89M
7 Day Performance	14.56%	3.03%	2.33%	0.57%
1 Month Performance	2.78%	9.82%	7.72%	4.90%
1 Year Performance	-59.35%	55.05%	25.22%	17.06%

Humacyte Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HUMA Humacyte	3.1341 of 5 stars	$0.64 flat	$6.11 +851.0%	-59.4%	$178.40M	$2.04M	N/A	150	Gap Up
SLN Silence Therapeutics	3.0233 of 5 stars	$14.35 +4.6%	$53.50 +272.8%	+148.0%	$648.22M	$560K	N/A	100
SVA Sinovac Biotech	N/A	$6.47 flat	N/A	N/A	$644.66M	$386.01M	N/A	3,008	High Trading Volume
FDMT 4D Molecular Therapeutics	3.0624 of 5 stars	$14.55 +19.4%	$29.63 +103.6%	+123.3%	$637.25M	$85.21M	N/A	120	Gap Up High Trading Volume
CBIO Crescent Biopharma	2.5429 of 5 stars	$17.48 +2.0%	$29.40 +68.2%	+13.9%	$636.65M	$10.84M	N/A	50

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HUMA) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Humacyte (HUMA) Competitors

HUMA vs. SLN, SVA, FDMT, CBIO, and MDXG

How does Humacyte compare to Silence Therapeutics?

Summary

How does Humacyte compare to Sinovac Biotech?

Summary

How does Humacyte compare to 4D Molecular Therapeutics?

Summary

How does Humacyte compare to Crescent Biopharma?

Summary

How does Humacyte compare to MiMedx Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HUMA vs. The Competition

Humacyte Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Humacyte (HUMA) Competitors

HUMA vs. SLN, SVA, FDMT, CBIO, and MDXG

How does Humacyte compare to Silence Therapeutics?

Does the media favor HUMA or SLN?

Which has higher valuation and earnings, HUMA or SLN?

Do insiders & institutionals have more ownership in HUMA or SLN?

Which has more volatility and risk, HUMA or SLN?

Do analysts recommend HUMA or SLN?

Is HUMA or SLN more profitable?

Summary

How does Humacyte compare to Sinovac Biotech?

Which has better earnings & valuation, HUMA or SVA?

Which has more volatility & risk, HUMA or SVA?

Do analysts rate HUMA or SVA?

Is HUMA or SVA more profitable?

Does the media favor HUMA or SVA?

Do institutionals and insiders have more ownership in HUMA or SVA?

Summary

How does Humacyte compare to 4D Molecular Therapeutics?

Does the media favor HUMA or FDMT?

Is HUMA or FDMT more profitable?

Do institutionals & insiders hold more shares of HUMA or FDMT?

Which has more risk and volatility, HUMA or FDMT?

Do analysts recommend HUMA or FDMT?

Which has preferable earnings & valuation, HUMA or FDMT?

Summary

How does Humacyte compare to Crescent Biopharma?

Do institutionals and insiders believe in CBIO or HUMA?

Does the media refer more to CBIO or HUMA?

Which has more volatility and risk, CBIO or HUMA?

Is CBIO or HUMA more profitable?

Which has higher earnings and valuation, CBIO or HUMA?

Do analysts prefer CBIO or HUMA?

Summary

How does Humacyte compare to MiMedx Group?

Does the media prefer HUMA or MDXG?

Do analysts prefer HUMA or MDXG?

Is HUMA or MDXG more profitable?

Which has more volatility & risk, HUMA or MDXG?

Which has stronger valuation and earnings, HUMA or MDXG?

Do institutionals & insiders believe in HUMA or MDXG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HUMA vs. The Competition

Humacyte Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools